Vaxcyte

Vaxcyte is a clinical-stage vaccine company dedicated to improving global health by developing superior and novel vaccines against common and deadly infectious diseases. Founded in 2013, the company operates within the Biotechnology, Pharmaceuticals, and Healthcare sectors, focusing on innovation and developing best-in-class preventative and therapeutic solutions. Vaxcyte leverages its proprietary vaccine platform to design complex antigens, aiming for enhanced effectiveness and protective capabilities against bacterial and viral pathogens. The company's mission is driven by the importance of creating impactful vaccines for significant public health challenges.

Headquartered in San Carlos, California, Vaxcyte employs between 500 - 1,000 individuals. This operational base supports its research and development efforts. Learn about Vaxcyte's global headquarters for detailed location information. The company's team is focused on advancing its pipeline of innovative vaccine candidates. Meet Vaxcyte's team to understand the expertise driving its scientific endeavors. Vaxcyte's product development centers on creating vaccines that offer significant advantages over existing options, addressing unmet medical needs in infectious disease prevention.

With a substantial funding history, including Series B, C, and D rounds, Vaxcyte has secured significant capital to advance its clinical programs. The company's financial strategy supports its ambitious development goals. Explore financial highlights for detailed insights into its funding and financial performance. Vaxcyte competes in a dynamic market with other biotechnology firms focused on vaccine development, including Gritstone Bio and YS Biopharma, aiming to establish leadership in critical areas of infectious disease prevention through scientific rigor and strategic execution.